TRIM22 and HIV-1 infection: They provided the first evidence that TRIM22 can restrict HIV-1 replication in vitro by showing that exogenous expression of TRIM22 inhibited HIV-1 infection by 50–90% in 293T cells modified to express the CD4 and CCR5 receptors and in primary MDM.